Elanco Animal Health (ELAN) | Financial Analysis & Statements
Elanco Animal Health Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.1B
Gross Profit
589.0M
51.49%
Operating Income
19.0M
1.66%
Net Income
-276.0M
-24.13%
Balance Sheet Metrics
Total Assets
13.4B
Total Liabilities
6.8B
Shareholders Equity
6.5B
Debt to Equity
1.04
Cash Flow Metrics
Operating Cash Flow
-30.0M
Free Cash Flow
46.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Elanco Animal Health Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.7B | 4.4B | 4.4B | 4.4B | 4.8B |
| Cost of Goods Sold | 2.1B | 2.0B | 1.9B | 1.9B | 2.1B |
| Gross Profit | 2.6B | 2.4B | 2.5B | 2.5B | 2.6B |
| Gross Margin % | 55.0% | 54.9% | 56.3% | 56.6% | 55.2% |
| Operating Expenses | |||||
| Research & Development | 368.0M | 344.0M | 327.0M | 321.0M | 369.0M |
| Selling, General & Administrative | 1.4B | 1.3B | 1.3B | 1.3B | 1.4B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.8B | 1.7B | 1.6B | 1.6B | 1.8B |
| Operating Income | 252.0M | 251.0M | 326.0M | 384.0M | 304.0M |
| Operating Margin % | 5.3% | 5.7% | 7.4% | 8.7% | 6.4% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 220.0M | 235.0M | 277.0M | 241.0M | 236.0M |
| Other Non-Operating Income | -256.0M | 472.0M | -1.2B | -215.0M | -639.0M |
| Pre-tax Income | -224.0M | 488.0M | -1.2B | -72.0M | -571.0M |
| Income Tax | 8.0M | 150.0M | 36.0M | 6.0M | -88.0M |
| Effective Tax Rate % | 0.0% | 30.7% | 0.0% | 0.0% | 0.0% |
| Net Income | -232.0M | 338.0M | -1.2B | -78.0M | -483.0M |
| Net Margin % | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% |
| Key Metrics | |||||
| EBITDA | 913.0M | 895.0M | 945.0M | 1.0B | 1.0B |
| EPS (Basic) | $-0.47 | $0.68 | $-2.50 | $-0.15 | $-0.97 |
| EPS (Diluted) | $-0.47 | $0.68 | $-2.50 | $-0.15 | $-0.97 |
| Basic Shares Outstanding | 496400000 | 494000000 | 492300000 | 488300000 | 487200000 |
| Diluted Shares Outstanding | 496400000 | 494000000 | 492300000 | 488300000 | 487200000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Elanco Animal Health Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 545.0M | 468.0M | 352.0M | 345.0M | 638.0M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 873.0M | 805.0M | 842.0M | 797.0M | 833.0M |
| Inventory | 1.7B | 1.6B | 1.7B | 1.5B | 1.4B |
| Other Current Assets | 236.0M | 287.0M | 310.0M | 394.0M | 237.0M |
| Total Current Assets | 3.5B | 3.2B | 3.4B | 3.3B | 3.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.3B | 990.0M | 985.0M | 941.0M | 1.4B |
| Goodwill | 13.0B | 12.5B | 14.7B | 16.8B | 17.9B |
| Intangible Assets | 3.4B | 3.7B | 4.5B | 4.8B | 5.6B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 304.0M | 311.0M | 341.0M | 378.0M | 390.0M |
| Total Non-Current Assets | 9.9B | 9.4B | 11.0B | 12.2B | 13.2B |
| Total Assets | 13.4B | 12.6B | 14.4B | 15.5B | 16.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 368.0M | 296.0M | 270.0M | 390.0M | 416.0M |
| Short-term Debt | 74.0M | 44.0M | 38.0M | 388.0M | 294.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 533.0M | 466.0M | 409.0M | 454.0M | 433.0M |
| Total Current Liabilities | 1.6B | 1.3B | 1.2B | 1.7B | 1.6B |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.9B | 4.3B | 5.7B | 5.4B | 6.0B |
| Deferred Tax Liabilities | 382.0M | 449.0M | 567.0M | 662.0M | 765.0M |
| Other Non-Current Liabilities | 427.0M | 302.0M | 411.0M | 229.0M | 262.0M |
| Total Non-Current Liabilities | 5.2B | 5.2B | 6.9B | 6.5B | 7.3B |
| Total Liabilities | 6.8B | 6.5B | 8.1B | 8.2B | 9.0B |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -2.2B | -2.0B | -2.3B | -1.1B | -979.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.5B | 6.1B | 6.2B | 7.3B | 7.5B |
| Key Metrics | |||||
| Total Debt | 4.0B | 4.3B | 5.8B | 5.8B | 6.3B |
| Working Capital | 1.9B | 1.9B | 2.2B | 1.6B | 1.6B |
Balance Sheet Composition
Elanco Animal Health Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -232.0M | 338.0M | -1.2B | -78.0M | -483.0M |
| Depreciation & Amortization | 680.0M | 662.0M | 694.0M | 682.0M | 716.0M |
| Stock-Based Compensation | 68.0M | 55.0M | 46.0M | 59.0M | 66.0M |
| Working Capital Changes | 99.0M | 149.0M | -300.0M | -462.0M | -88.0M |
| Operating Cash Flow | 489.0M | 1.1B | -803.0M | 351.0M | 138.0M |
| Investing Activities | |||||
| Capital Expenditures | -276.0M | -147.0M | -140.0M | -171.0M | -159.0M |
| Acquisitions | 9.0M | 1.3B | -19.0M | 0 | -342.0M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -279.0M | 1.2B | -155.0M | -166.0M | -492.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 2.4B | 570.0M | 600.0M | 988.0M | 1.0B |
| Debt Repayment | -2.9B | -2.0B | -677.0M | -1.5B | -823.0M |
| Financing Cash Flow | -275.0M | -1.5B | -83.0M | -799.0M | 460.0M |
| Free Cash Flow | 284.0M | 380.0M | 117.0M | 268.0M | 286.0M |
| Net Change in Cash | -65.0M | 780.0M | -1.0B | -614.0M | 106.0M |
Cash Flow Trend
Elanco Animal Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
377.14
Forward P/E
19.35
Price to Book
1.72
Price to Sales
2.39
PEG Ratio
0.14
Profitability Ratios
Profit Margin
-4.92%
Operating Margin
2.27%
Return on Equity
-3.67%
Return on Assets
1.25%
Financial Health
Current Ratio
2.16
Debt to Equity
67.89
Beta
1.88
Per Share Data
EPS (TTM)
$-0.47
Book Value per Share
$13.17
Revenue per Share
$9.50
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ELAN | 11.2B | 377.14 | 1.72 | -3.67% | -4.92% | 67.89 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| United Therapeutics | 25.1B | 20.60 | 3.53 | 19.72% | 41.94% | 0.53 |
| Viatris | 17.0B | 235.80 | 1.15 | -21.08% | -24.58% | 99.91 |
| Intra-Cellular | 14.0B | -183.15 | 12.20 | -8.58% | -10.97% | 1.48 |
Financial data is updated regularly. All figures are in the company's reporting currency.






